Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249301 · ClinicalTrials.gov registry record · Phase 1
A Study of MLN8054 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT00249301: Clinical Trial Phase 1 study, sponsored by Millennium Pharmaceuticals.
NCT00249301 is a Phase 1 study that was terminated before completion, run by Millennium Pharmaceuticals. The registered enrollment target is 63 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00249301, a Phase 1 study, was terminated before completion, sponsored by Millennium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to determine (1) The side effects or toxicities of MLN8054;(2) The highest dose where side effects or toxicities are not too severe; (3) How MLN8054 is absorbed into the general blood circulation and eliminated from the body; and (4) The levels of MLN8054 in the blood that are needed to inhibit Aurora A kinase.
Interventions
- DRUG MLN8054
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2005-10 |
| Phase | Phase 1 |
Why NCT00249301 stopped before completion
NCT00249301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which MLN8054 is the first listed.
NCT00249301 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00249301 about?
NCT00249301 is a clinical study titled "A Study of MLN8054 in Patients With Advanced Solid Tumors". The purpose of this study is to determine (1) The side effects or toxicities of MLN8054;(2) The highest dose where side effects or toxicities are not too severe; (3) How MLN8054 is absorbed into the general blood circulation and eliminated from the body; and (4) The levels of MLN8054 in the blood th...
What is the current status of trial NCT00249301?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2005-10.
What interventions are being tested in trial NCT00249301?
The interventions under investigation include: MLN8054 (DRUG).
Who is sponsoring clinical trial NCT00249301?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00249301's enrollment target sits among peer trials
63 820th of 2000 higher than 1,177 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia